<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750772</url>
  </required_header>
  <id_info>
    <org_study_id>XW-YZ-FAPI-2019KT95</org_study_id>
    <nct_id>NCT04750772</nct_id>
  </id_info>
  <brief_title>Positron Nuclide Labeled NOTA-FAPI PET Study in Colocrectal Cancer</brief_title>
  <official_title>Comparison of Positron Nuclide Labeled NOTA-FAPI PET and FDG PET Study in Colocrectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the normal physiological distribution of positron nuclide labeled NOTA-FAPI in&#xD;
      human body and its detection efficiency for colorectal cancers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects first undergo an 18F-FDG test, followed by 68Ga-NOTA-FAPI04 or 18F-NOTA-FAPI04 test&#xD;
      in groups. The purpose of the comparison of the maximum of standardized uptake value(SUVmax )&#xD;
      between 68Ga/18F-NOTA-FAPI04 and 18F-FDG PET/CT for the target lesion of colorectal cancer is&#xD;
      to investigate the superiority of FAPI in diagnosis of colorectal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax</measure>
    <time_frame>60days</time_frame>
    <description>Standardized uptake value of 68Ga/ 18F-NOTA-FAPI04 for target lesion of subject or suspected tumor in each time point window (SUV)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tumor, Solid</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-FAPI04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-NOTA-FAPI04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG and 68Ga-NOTA-FAPI04 PET/CT</intervention_name>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
    <arm_group_label>68Ga-NOTA-FAPI04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG and 18F-NOTA-FAPI04 PET/CT</intervention_name>
    <description>Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time</description>
    <arm_group_label>18F-NOTA-FAPI04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG score 0-2&#xD;
&#xD;
          -  subjects with colorectal cancer with/without therapy or suspected tumor subjects who&#xD;
             have recently (within 2 months) planned to receive pathological biopsy or tumor&#xD;
             surgery&#xD;
&#xD;
          -  expected survival ≥12 weeks&#xD;
&#xD;
          -  blood routine, liver and kidney function meet the following criteria: blood routine:&#xD;
             WBC≥4.0×109L or neutrophils ≥1.5×109L, PLT≥100×109/L, Hb≥90g/L;PT and APTT ULN 1.5 or&#xD;
             less;Liver and kidney function: t-bil ≤1.5×ULT(upper limit of normal value),&#xD;
             ALT/AST≤2.5ULN or ≤5×ULT(subjects with liver metastasis), ALP≤2.5ULN(ALP≤ 4.5ULN if&#xD;
             there is bone metastasis or liver metastasis);BUN 1.5 x or less ULT, SCr 1.5 x or less&#xD;
             ULT&#xD;
&#xD;
          -  at least one measurable target lesion according to RECIST1.1&#xD;
&#xD;
          -  women must use effective contraception during the study period and for 6 months after&#xD;
             the end of the study (effective contraception means sterilization, hormone devices,&#xD;
             condoms, contraceptives/pills, abstinence or vasectomy by a partner, etc.);Men should&#xD;
             consent to subjects who must use contraception during the study period and for 6&#xD;
             months after the end of the study period&#xD;
&#xD;
          -  able to understand and sign the informed consent voluntarily, with good compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe abnormalities of liver and kidney function;&#xD;
&#xD;
          -  women preparing for pregnancy, pregnancy and lactation;&#xD;
&#xD;
          -  cannot lie supine for half an hour;&#xD;
&#xD;
          -  refuse to join the clinical researcher;&#xD;
&#xD;
          -  suffering from claustrophobia or other mental illness;&#xD;
&#xD;
          -  conditions that other researchers considered inappropriate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Yang</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuejuan Wang, MD</last_name>
    <phone>86 010 88196363</phone>
    <email>xuejuan_wang@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi Yang, PHD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuejuan Wang, MD</last_name>
      <phone>86 10-88196363</phone>
      <email>xuejuan_wang@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Xuejuan Wang,MD</investigator_full_name>
    <investigator_title>Deputy Director of Nuclear Medicine</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>FAPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

